ライフサイエンスコーパス: live attenuated vaccine

1 VS::Deltawzy, was created and evaluated as a live attenuated vaccine.

2 tivated vaccine as compared with those given live attenuated vaccine.

3 ed vaccine and 36% (95% CI, 0 to 59) for the live attenuated vaccine.

4 sting that the M2KO virus has potential as a live attenuated vaccine.

5 nts that can be used in the development of a live attenuated vaccine.

6 nd virulence to preclude its direct use as a live attenuated vaccine.

7 -2 may be a potential candidate for use as a live attenuated vaccine.

8 onse was of longer duration in recipients of live attenuated vaccine.

9 th -19% (95% CI, -113 to 33; P=0.55) for the live attenuated vaccine.

10 culated for the inactivated vaccines and the live attenuated vaccine.

11 ping a safe and potentially more efficacious live attenuated vaccine.

12 l tropism of a virus is a new approach for a live attenuated vaccine.

13 entially serve as a positive-marker modified live-attenuated vaccine.

14 ored ILTV vaccines are less efficacious than live attenuated vaccines.

15 onally attenuate hMPV for the development of live attenuated vaccines.

16 man paramyxoviruses for rationally designing live attenuated vaccines.

17 gy, which combines the advantages of DNA and live attenuated vaccines.

18 s that can be mutated to generate successful live attenuated vaccines.

19 from that induced by live virus and possibly live attenuated vaccines.

20 factors, and may differ for inactivated and live attenuated vaccines.

21 use of non-toxigenic C. difficile strains as live attenuated vaccines.

22 nother approach for prevention is the use of live attenuated vaccines.

23 irion inactivated vaccines and cold-adapted, live attenuated vaccines.

24 ied for development of classical swine fever live attenuated vaccines.

25 had poor or diminished efficacy compared to live attenuated vaccines.

26 characteristics desirable in candidates for live attenuated vaccines.

27 derivatives of these pathogens may serve as live attenuated vaccines.

28 enesis and the design of a new generation of live attenuated vaccines.

29 r antiviral discovery and development of new live attenuated vaccines.

30 o understand virus biology and develop novel live attenuated vaccines.

31 n vivo and supports targeting the SH gene in live attenuated vaccines.

32 ations are good candidates for the design of live attenuated vaccines.

33 cell culture has hindered the development of live-attenuated vaccines.

34 ruses with vhs deleted have been proposed as live-attenuated vaccines.

35 quence identities (>/=98%) with the modified live-attenuated vaccines.

36 development of antivirals and the design of live-attenuated vaccines.

37 luable for the development of antivirals and live-attenuated vaccines.

38 ty and activity is a strategy for generating live-attenuated vaccines.

39 ize may be more informative on the safety of live-attenuated vaccines.

40 option as safe, immunogenic, and protective live-attenuated vaccines.

41 after receipt of dose 1 among recipients of live attenuated vaccine (3.8%) than among recipients of

42 We propose that this live attenuated vaccine acts like a silent natural infec

43 Immunization with live, attenuated vaccine (administered intranasally) is

44 s used to develop a two-component, trivalent live attenuated vaccine against human parainfluenza viru

45 defined F. novicida mutant (DeltaiglC) as a live attenuated vaccine against subsequent intranasal ch

46 related mainly to reduced protection of the live attenuated vaccine against type B viruses.

47 unique possibilities for developing improved live attenuated vaccines against arteriviruses and other

48 natural infection and strategies to develop live attenuated vaccines against flaviviral species.IMPO

49 mid-deficient chlamydial strains function as live attenuated vaccines against genital and ocular infe

50 2 cytoplasmic tail mutants have potential as live attenuated vaccines against H5N1 influenza viruses.

51 the feasibility of using M2 tail mutants as live attenuated vaccines against H5N1 virus.

52 s study may aid in the design of efficacious live attenuated vaccines against PEDV, as well as other

53 d and the polymerase could be used to design live attenuated vaccines against serious pathogens withi

54 on genetic engineering techniques--to design live attenuated vaccines against some of these viral age

55 gement provides a new approach to generating live attenuated vaccines against this class of virus.

56 At least 14 different live attenuated vaccines against this pathogen are avail

57 ChimeriVax-JE is a live, attenuated vaccine against Japanese encephalitis,

58 rtant implications for developing a modified live-attenuated vaccine against HEV.

59 ctious DNA clone as a genetically engineered live-attenuated vaccine against PCV2 infection and PMWS.

60 ications for development of both subunit and live-attenuated vaccines against ETEC and other enteric

61 ectors show significant promise as potential live-attenuated vaccines against human immunodeficiency

62 A similar approach may guide the design of live-attenuated vaccines against Lassa and other arenavi

63 The live attenuated vaccine also prevented influenza illness

64 However, live attenuated vaccines also induce strong CD8 T cell r

65 88(-/-) and Card9(-/-) mice immunized with a live, attenuated vaccine also fail to acquire protective

66 Among live attenuated vaccine and placebo recipients, cases we

67 may be a novel target for rational design of live attenuated vaccines and antiviral drugs.

68 placebo-controlled trial of inactivated and live attenuated vaccines and compared titers in subjects

69 egions display characteristics desirable for live attenuated vaccines and hold potential as vaccine c

70 sible association between revaccination with live attenuated vaccines and off-target infections are n

71 r quality control of new lots of the current live-attenuated vaccine and provide insight for the rati

72 nform the development of rationally-designed live-attenuated vaccines and antivirals for control of o

73 fe for mucosal application in humans, use of live-attenuated vaccines and microbial vectors, and prod

74 placebo-controlled trial of inactivated and live attenuated vaccines, and we evaluated the laborator

75 rts superseded by a final report, studies of live-attenuated vaccine, and studies of prepandemic seas

76 mmune responses similar to those elicited by live-attenuated vaccines, and its flexibility permits th

77 Live attenuated vaccines appear to be the most effective

78 vaccine appeared to be efficacious, whereas live attenuated vaccine appeared to be less so.

79 Our results suggest that the live attenuated vaccine approach should remain a viable

80 However, the live-attenuated vaccine approach faces formidable obstac

81 logous virus challenge and suggest that even live, attenuated vaccine approaches for AIDS will face s

82 Novel live attenuated vaccines are being developed that promis

83 Live attenuated vaccines are commonly used in the poultr

84 Live attenuated vaccines are considered the most viable

85 okines to enhance the safety and efficacy of live attenuated vaccines are discussed.

86 Live attenuated vaccines are more immunogenic and have t

87 Live attenuated vaccines are traditionally generated by

88 Although live, attenuated vaccines are available to protect sever

89 ing and the potential to develop multivalent live-attenuated vaccines are discussed.

90 ion may serve as a novel approach to develop live attenuated vaccines as well as antiviral drugs for

91 The superior efficacy of live attenuated vaccine, as compared with inactivated va

92 tivity can lead to the development of novel, live attenuated vaccines, as well as antiviral drugs for

93 F) 17D vaccine is one of the most successful live attenuated vaccines available.

94 consideration should be taken when designing live attenuated vaccines based on deletions of nonstruct

95 new avenue for the development of arenavirus live attenuated vaccines based on rearrangement of their

96 al virulence factors, we hypothesized that a live-attenuated vaccine based on PA14 might elicit a bro

97 A single inoculation of the RVF MP-12 live attenuated vaccine by the aerosol or intranasal rou

98 a potentially general approach for creating live-attenuated vaccines by introducing mutations result

99 Although live attenuated vaccines can provide potent protection a

100 oid of the p27 gene could be considered as a live attenuated vaccine candidate against visceral leish

101 cine is not available, and the more advanced live attenuated vaccine candidate in clinical trials req

102 P130 was then assessed for its efficacy as a live attenuated vaccine candidate in mice after challeng

103 human parainfluenza virus type 3 (PIV3) cp45 live attenuated vaccine candidate.

104 est that Delta3678 SARS-CoV-2 may serve as a live-attenuated vaccine candidate and a research tool fo

105 und that the immunogenicity in primates of a live-attenuated vaccine candidate for parainfluenza viru

106 Currently, the most promising live-attenuated vaccine candidate is a temperature-sensi

107 To control TMUV infection, a live-attenuated vaccine candidate of TMUV was developed

108 Here we report on a live-attenuated vaccine candidate that contains a 10-nuc

109 Unlike HEp-2 cells, in which wild-type and live-attenuated vaccine candidate viruses grow equally w

110 Chimeric live-attenuated vaccine candidate YF-ZIK previously show

111 eltarelA DeltaspoT mutant may be a promising live-attenuated vaccine candidate.

112 In our research, we developed novel live attenuated vaccine candidates against chikungunya v

113 enza viruses might have a great potential as live attenuated vaccine candidates against SIV infection

114 of gene rearrangement as a means to develop live attenuated vaccine candidates against Vesicular sto

115 rational development of safe and protective live attenuated vaccine candidates based on genome reorg

116 We have generated new influenza A virus live attenuated vaccine candidates by site-directed muta

117 ps but also will lead to the development new live attenuated vaccine candidates for hMPV.

118 tical information for the rational design of live attenuated vaccine candidates for other viral hemor

119 thylation as a target for rational design of live attenuated vaccine candidates for RSV and perhaps o

120 can be assembled and have been developed as live attenuated vaccine candidates for several flaviviru

121 h potential for further development as novel live attenuated vaccine candidates that may rapidly cont

122 This strategy may be useful for generating live attenuated vaccine candidates that prevent disease

123 to safely attenuate FMDV and further develop live attenuated vaccine candidates to control such a fea

124 mmunogenicity, justifying their inclusion in live attenuated vaccine candidates to protect against th

125 ified deISGylase activity for development of live attenuated vaccine candidates, and ISG15 as a novel

126 use of this strain to evaluate the safety of live attenuated vaccine candidates.

127 t hosts, and this has motivated a search for live attenuated vaccine candidates.

128 nymous but suboptimal substitutions provides live attenuated vaccine candidates.

129 could form the basis of a new generation of live attenuated vaccine candidates.

130 bility of a CD-based approach for developing live-attenuated vaccine candidates against human-pathoge

131 We therefore generated 2 live-attenuated vaccine candidates based on the insertio

132 tion and provides an approach for generating live-attenuated vaccine candidates for emerging coronavi

133 tor escape mutants and mutations observed in live-attenuated vaccine candidates.

134 ost tissues, and identification of potential live-attenuated vaccine candidates.

135 The current live attenuated vaccines (chicken embryo origin [CEO] an

136 immunogenicity and protective efficacy of a live attenuated vaccine consisting of a recombinant seve

137 of mixed viral populations and indicate that live-attenuated vaccines containing virulent virus may b

138 an a subunit vaccine, such as a whole-virus, live-attenuated vaccine, could confer improved protectio

139 eriVax-Japanese encephalitis (JE), the first live- attenuated vaccine developed with this technology

140 versus lower respiratory tract and bear upon live attenuated vaccine development.

141 lso boost the immunogenicity and efficacy of live attenuated vaccines directed against shigellosis, t

142 ach to the development of safe and effective live attenuated vaccines directed against VEEV and other

143 ach to the development of safe and effective live attenuated vaccines directed against VEEV and perha

144 esence of virulent revertant viruses in some live-attenuated vaccines, disease from vaccination is ra

145 Thus far, the goal of developing a safe, live attenuated vaccine effective after a single dose ha

146 Thus, multivalent live-attenuated vaccines elicit multifactorial protectiv

147 Isolation frequency was lowest among live attenuated vaccine failures, a reflection of lower

148 tive immune response and may have value as a live attenuated vaccine for aquaculture.

149 We previously reported that an experimental live attenuated vaccine for equine infectious anemia vir

150 to consideration when one is contemplating a live attenuated vaccine for HIV-1.

151 Development of a live attenuated vaccine for human NoV has not been possi

152 tein is an approach to designing a promising live attenuated vaccine for PEDV.

153 The absolute efficacies of the live attenuated vaccine for these end points were 8% (95

154 The recently licensed live attenuated vaccine for varicella-zoster virus is ef

155 oach for development of safe and efficacious live attenuated vaccines for AIDS.

156 serve as a novel target to rationally design live attenuated vaccines for aMPV and perhaps other para

157 rstanding may also enable the development of live attenuated vaccines for both RSV and other members

158 predicted to be safe, antibiotic-sensitive, live attenuated vaccines for cholera due to the O139 ser

159 The utility of live attenuated vaccines for controlling HIV epidemics i

160 for the development of safe and efficacious live attenuated vaccines for hMPV and other human paramy

161 serve as a novel target to rationally design live attenuated vaccines for hMPV and perhaps other para

162 a master donor strain for the generation of live attenuated vaccines for humans and livestock.

163 aches would add an HPV component to existing live attenuated vaccines for measles and typhoid fever.

164 s but also facilitate the development of new live attenuated vaccines for VSV, and perhaps other NNS

165 least a decade is required for approval of a live, attenuated vaccine for use in humans.

166 We developed an experimental live-attenuated vaccine for direct inoculation of the re

167 A live-attenuated vaccine for RVF, the MP-12 vaccine, is c

168 ovided an opportunity to design a successful live-attenuated vaccine for SARS-CoV and opens avenues f

169 Therefore, NU14 DeltawaaL is a candidate live-attenuated vaccine for the treatment and prevention

170 JUNV), indicating the potential of TCRV as a live-attenuated vaccine for the treatment of Argentine h

171 novel approach to produce safe and effective live-attenuated vaccines for DENV and other insect-borne

172 Two live-attenuated vaccines for gastroenteritis (Rotateq [M

173 unosuppression and aid in the development of live-attenuated vaccines for IBDV.

174 NV vaccine constructs use the E protein in a live attenuated vaccine format, utilizing a backbone der

175 Among young children, live attenuated vaccine had significantly better efficac

176 ses (CoVs), and the inactivation of nsp16 in live attenuated vaccines has been attempted for several

177 Development of live, attenuated vaccines has traditionally relied on em

178 aluated in various animal lentivirus models, live attenuated vaccines have proven to be the most effe

179 Live, attenuated vaccines have prevented morbidity and m

180 Although live-attenuated vaccines have been safely administered t

181 However, the existing live-attenuated vaccines have the potential to revert to

182 RSV DeltaSH has been tested as a live attenuated vaccine in humans and cattle, and here w

183 eficient Chlamydia trachomatis to serve as a live attenuated vaccine in the genital tract.

184 h more serious adverse events than any other live attenuated vaccine in use today.

185 the protective immune mechanisms induced by live attenuated vaccines in primate models will be usefu

186 n eggs and has the potential to be used as a live-attenuated vaccine in humans.

187 s as a model to analyze characteristics of a live-attenuated vaccine in protection against virus-indu

188 Because concerns exist about the use of live-attenuated vaccines in immunocompromised individual

189 All eight live attenuated vaccines, including Japanese encephaliti

190 adjuvanted inactivated vaccine, but not the live-attenuated vaccine, induced a substantial serum IgG

191 required to further define the nature of the live, attenuated vaccine-induced immunity against Coccid

192 V biology, including human host-pathogen and live, attenuated vaccine interactions; host and cell typ

193 ective vaccine than the previously developed live attenuated vaccine is needed for combating Francise

194 f adaptive immune response generated to this live attenuated vaccine is regulated by both the presenc

195 A live attenuated vaccine is the most promising vaccine st

196 /LASV reassortant (ML29) is a LASV candidate live-attenuated vaccine (LAV) that has shown promising r

197 ain Edmonston-Zagreb has long been used as a live-attenuated vaccine (LAV) to protect against measles

198 Implementation of live-attenuated vaccines (LAV) will represent a major st

199 ty and the convenient administration routes, live attenuated vaccines (LAVs) are promising arms for c

200 Vaccination with live attenuated vaccines (LAVs) is an effective way for

201 Live-attenuated vaccines (LAVs) are the most advanced va

202 RSV live-attenuated vaccines (LAVs) have a history of safe t

203 Implementation of live-attenuated vaccines (LAVs) will represent a major s

204 Different from classical live-attenuated vaccines, live-attenuated recombinant va

205 challenge in a goat model as compared to the live attenuated vaccine MAP316F.

206 ve immunity in individuals unable to receive live, attenuated vaccines may have employment implicatio

207 accines are ineffective or when the use of a live attenuated vaccine might be unsafe.

208 Successful live attenuated vaccines mimic natural exposure to patho

209 Boosting T cell-mediated immunity by live attenuated vaccine Mycobacterium bovis bacillus Cal

210 detected in mice immunized with the current live attenuated vaccine, Mycobacterium bovis-bacillus Ca

211 gimens included a chimeric H8/1, intranasal, live-attenuated vaccine on day 1 followed by a non-adjuv

212 ess and safety concerns regarding the use of live attenuated vaccines or potent adjuvants in this pop

213 f TCRV and to explore its potential use as a live-attenuated vaccine or a vaccine vector for the trea

214 logy of TCRV and also its potential use as a live-attenuated vaccine or a vaccine vector for the trea

215 Implementation of TCRV as a live-attenuated vaccine or a vaccine vector would be fac

216 ammarenaviruses, for their implementation as live-attenuated vaccines or vaccine vectors.IMPORTANCE T

217 The multivalent live-attenuated vaccines overcame prior problems involvi

218 us, opening the possibility for its use as a live-attenuated vaccine platform for ZIKV and other clin

219 , we report the development of a recombinant live-attenuated vaccine platform strain that retains the

220 viral NS1 protein have emerged as promising live attenuated vaccine platforms.

221 As modified mRNA and live-attenuated vaccine platforms can restrict in utero

222 s a novel technology to sufficiently deliver live attenuated vaccine powders into the skin.

223 Live-attenuated vaccines present safety challenges, and

224 However, only the live, attenuated vaccine prevented immunosuppression-ind

225 Although a live-attenuated vaccine protects against MV, vaccination

226 nfluenza A (H3N2), 90% of placebo and 87% of live attenuated vaccine recipients but only 23% of inact

227 ive lymphocytes after immune activation with live attenuated vaccines remain poorly characterized.

228 Live-attenuated vaccines represent an attractive immuniz

229 In 1988, an inexpensive live-attenuated vaccine (SA14-14-2) was licensed in Chin

230 ion of the risks and benefits indicates that live attenuated vaccine should be a highly effective, sa

231 The use of live attenuated vaccines should be limited to specific s

232 Finally, using the mutant as a live-attenuated vaccine showed significant promise for p

233 O-antigen polymerase) deletion mutant of Ft. live attenuated vaccine strain (Ft.LVS), designated Ft.L

234 udomallei Deltaasd mutant may be a promising live attenuated vaccine strain and a biosafe strain for

235 The live attenuated vaccine strain Candid #1 (Can) is approv

236 nscriptomic analysis of the M. gallisepticum live attenuated vaccine strain F and the virulent strain

237 A desirable trait in an effective live attenuated vaccine strain is an ability to persist

238 tularensis organisms were comparable to the live attenuated vaccine strain of Francisella tularensis

239 A candidate live attenuated vaccine strain was constructed for West

240 ve of SC602 (icsA iuc), a well-characterized live attenuated vaccine strain which has undergone sever

241 We used the live attenuated vaccine strain YFV-17D, which contains m

242 ens and livers than SL3261, the aroA mutant, live attenuated vaccine strain.

243 Whereas an F. tularensis live, attenuated vaccine strain (LVS) is the basis of an

244 th protection against plague, we developed a live-attenuated vaccine strain by deleting the Braun lip

245 tibility of the glycoprotein of the Candid#1 live-attenuated vaccine strain of JUNV in MACV replicati

246 sing reverse genetics, a set of experimental live attenuated vaccine strains based on recombinant H5N

247 throughout the poliovirus genome yielded the live attenuated vaccine strains of poliovirus.

248 Live attenuated vaccine strains of pseudorabies virus (P

249 Although live attenuated vaccine strains of simian immunodeficien

250 tive) strains of Salmonella may be useful as live attenuated vaccine strains or as vehicles for heter

251 Live attenuated vaccine strains, such as type I nonrepli

252 rae and a strong proinflammatory reaction to live attenuated vaccine strains.

253 on might be used to reduce reactogenicity of live attenuated vaccine strains.

254 aluating the neurovirulence potential of new live, attenuated vaccine strains and may also be of valu

255 coding engineered polymerases might serve as live, attenuated vaccine strains.

256 ge could be harnessed for the development of live-attenuated vaccine strains to combat HFAs.

257 lian host and warrant further development as live-attenuated vaccine strains.

258 A major safety concern of using live-attenuated vaccine strategies against AIDS is the p

259 er, the risk of vaccine-induced disease with live-attenuated vaccines strongly limits their use.

260 Live attenuated vaccines such as SIV with a deleted nef

261 nfirmed influenza in the group that received live attenuated vaccine than in the group that received

262 dministration of dose 1 was more common with live attenuated vaccine than with inactivated vaccine, p

263 that might be deleted for the development of live attenuated vaccines that would be safer to use in s

264 e describe the first genetically engineered, live, attenuated vaccine that protects both BALB/c and C

265 sease has resulted in the development of two live, attenuated vaccines that are now licensed in many

266 We describe a live-attenuated vaccine that is safe and efficacious in

267 Thus, it might be possible to develop live-attenuated vaccines that are as immunogenic as pare

268 As a safe alternative to live attenuated vaccines, the immunogenicity and protect

269 Similar to a live attenuated vaccine, this approach should allow immu

270 e candidates demonstrate the potential for a live attenuated vaccine to protect against disease cause

271 nal Institutes of Health (NIH) has developed live attenuated vaccines to each of the 4 serotypes of d

272 veral Yersinia species have been utilized as live attenuated vaccines to prime protective immunity ag

273 n scavenging host iron and have been used in live-attenuated vaccines to combat plague epidemics.

274 Live-attenuated vaccines typically offer rapid and durab

275 use of heterologous flavivirus species as a live attenuated vaccine vector is not likely to generate

276 ntigens expressed from multicopy plasmids in live attenuated vaccine vector strains of Vibrio cholera

277 ecombinant Sendai virus (rSeV) was used as a live, attenuated vaccine vector for intranasal inoculati

278 vivo expression of heterologous antigens by live, attenuated vaccine vector strains of Vibrio choler

279 nstrating the feasibility of using TCRV as a live-attenuated vaccine vector for the treatment of JUNV

280 Live attenuated vaccine vectors based on recombinant ves

281 Vaccination of mice with a live attenuated vaccine virus induces potent protection

282 Immunization with a live attenuated vaccine virus prior to challenge protect

283 e findings show that the immunogenicity of a live-attenuated vaccine virus in primates can be enhance

284 tally increase the level of attenuation of a live-attenuated vaccine virus.

285 redictive of restricted viral replication of live attenuated vaccine viruses in humans.

286 t remains unclear whether the replication of live attenuated vaccine viruses will be similarly enhanc

287 ic attenuation and host-range restriction of live attenuated vaccine viruses.

288 However, the live attenuated vaccine was found to be ineffective amon

289 fective (95% CI, 47 to 70; P<0.001), and the live attenuated vaccine was not observed to be effective

290 t the stalk and catalytic domains of NA as a live attenuated vaccine was shown to confer a strong IAV

291 The efficacy of the live attenuated vaccine was slightly less than that of t

292 he 2016-2017 A(H1N1)pdm09 strain used in the live attenuated vaccine was unchanged from 2015-2016, th

293 The live-attenuated vaccine was used to assess the impact of

294 The absolute efficacies of the live attenuated vaccine were 57% (95% CI, -3 to 82), 48%

295 ruses and human infections, new candidate H5 live attenuated vaccines were developed by using two dif

296 cination were higher among the recipients of live attenuated vaccine who were 6 to 11 months of age (

297 ent and control are under development, and a live attenuated vaccine with substantial potential for c

298 vaccine and 29% (95% CI, -14 to 55) for the live attenuated vaccine, with a relative efficacy of 60%

299 A single intranasal administration of live attenuated vaccine without adjuvant was sufficient

300 An effective live attenuated vaccine would be extremely useful in the